CoV-50-Test, molecular detection of the course of complications of a Covid-19 disease.
The DiaPat-CoV-50-Test or Test-Combination is currantly only availible in Germany under the conditions described below.
DiaPat-CoV-50 test, molecular detection of the course of complications of a Covid-19 disease.
The test is only for patients with a proven SARS-CoV-2 infection. Inclusion criterion is a positive PCR result. Exclusion criteria are urinary tract infection or symptom nephrolitiasis.
The test will be sent to your doctor or you immediately, according to your instructions, and you and your doctor will find out where and when the urine will be given.
In view of the legal situation for in-vitro diagnostics of the EU directive, all DiaPat tests, such as urine output, are only to be carried out under the instruction of a doctor and the patient is only to be given the diagnostic results by him. The urine sample taken is then sent to us for analysis.
The results will then be sent to your treating doctor, with whom you can clarify any further measures that may be necessary.
The DiaPat-CoV-50 test costs 850 euros
If you only order the DiaPat-CoV-50 test as a preventive measure, one of the following alternative tests can be carried out as a replacement, if it is not used
a. molecular, early detection of chronic kidney disease (DiaPat-CKD-273 + 7) or
b. Heart failure and coronary heart disease.
The DiaPat-CoV-50 test has received the approval!
Patients who have tested positive for Covid-19 with a PCR test can now determine at an early stage whether they are facing a serious course, which they can prevent with timely medication. The patients concerned can obtain the simple DiaPat-CoV-50 test from urine directly from their family doctor or their local clinic.
The DiaPat-CoV-50 test is currently not reimbursed by the federal government and is not included in the payment catalog of the statutory health insurance companies. To the best of our knowledge, there is no DRG to avoid serious disease progression in Covid-19 patients, which the clinics can bill.
The early - prognostic - detection of the complication course of Covid 19 by the DiaPat-CoV-50 test enables the timely use of medication and prevents intensive medical treatment and the use of ventilators - saves lives and eliminates the need for lockdown measures!
Once a Covid-19 disease has been identified, it can be determined whether the patient has a
- light (WHO grade 1-3 - no inpatient stay, no ventilation requirement)
- severe (WHO grade 4-5 - inpatient surveillance, no intensive care measures yet)
- very severe (WHO grade 6 - intensive care measures, mechanical ventilation if necessary)
Course and can thus receive various therapeutic agents in good time to prevent severe courses and thus save lives.
All studies to date show the benefits of therapeutic use in the early phase of Covid-19. Only then is the individualized dosage and coordination of the different medicinal effects possible efficiently. This results from the mechanism of action of the drugs alone:
- either: reduction of the viral load
- or: Reduction of the excessive immune reaction
If there is organ damage caused by an uncontrolled Covid-19 disease, it can no longer be "repaired". Therapy would come too late. If previous damage by the endothelium in the organ vessels due to chronic cardiovascular and kidney diseases is not recognized and therefore not taken into account, the prognosis of the course of Covid-19 is all the more urgent. An overview of the individual therapeutic effects and limitations Remdesivir and in particular antibodies against SARS-CoV-2 are only available to a limited extent and have significant side effects. Prophylactically, these therapeutics cannot be administered to all patients with Covid-19. Antibodies are effective, but hardly available therapeutics. Steroids are effective in the early stages, but have significant side effects. The compromise of the immune system also favors secondary infections, which is why steroids may only be used in a targeted manner.